Oncotelic Therapeutics Highlighted in BioMedWire Editorial as Drug-Delivery Market Nears $410 Billion

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a BioMedWire editorial that examines the expanding global drug-delivery market, which is projected to reach an estimated $410 billion opportunity. The editorial highlights increasing investor interest in platform biotech companies that are developing innovative solutions to overcome challenges in drug penetration, tumor targeting, therapeutic resistance, and maintaining consistent intratumoral exposure.

Oncotelic’s Sapu003 and Deciparticle platform are spotlighted as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance. These platforms aim to address critical limitations in current treatments by enabling more effective targeting and sustained release of therapeutic agents.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes innovative, late-stage therapeutic candidates. Additionally, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.

The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

As the drug-delivery market expands, the ability to improve how therapies are administered and targeted becomes increasingly important. Oncotelic’s platforms represent a potential leap forward in addressing some of the most persistent challenges in oncology, including resistance and poor drug penetration. The editorial suggests that companies with proprietary delivery technologies could capture significant value as the market grows.

For more information, the full press release is available at https://ibn.fm/laaQ6. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Highlighted in BioMedWire Editorial as Drug-Delivery Market Nears $410 Billion.

The post Oncotelic Therapeutics Highlighted in BioMedWire Editorial as Drug-Delivery Market Nears $410 Billion appeared first on citybuzz.